BridgeBio Pharma heads into its July 31 earnings print with one of the sharpest options sentiment reversals in the past year — even as the stock has climbed 24% in a month.
The options market is flashing a warning that stands apart from recent trends. The put/call ratio jumped to 1.24 on July 21 — a full four standard deviations above its 20-day average of 0.25, and the highest reading in the past 52 weeks. For context, every prior session in the history window sat below 0.20. That single-session spike represents a dramatic and sudden shift toward downside protection, almost certainly tied to pre-earnings hedging ahead of the July 31 release. The timing is telling: one day earlier the PCR was 0.20, indistinguishable from the prior three weeks.
Short positioning tells a different story — one of scale rather than urgency. Short interest holds at 12.7% of free float, roughly 24.5 million shares, a level that has been broadly stable for weeks. The week-on-week change is essentially flat at -0.4%. More importantly, the lending market remains extremely loose: availability runs at 1,328% — meaning there are more than thirteen shares available to borrow for every one currently lent out. Cost to borrow is a modest 0.53%, well within the low range. Shorts here are structural, not a squeeze candidate. The ORTEX short score has drifted between 57.8 and 59.6 over the past two weeks, and at the 27th percentile on short score rank, there is no sign of a fresh short-selling wave building.
The Street is broadly constructive, but the consensus has nuance. Two target raises arrived in the past ten days: Citigroup lifted its Neutral-rated target from $82 to $93, and HC Wainwright raised its Buy target to $120 from $110. Morgan Stanley already moved its Overweight target to $98 in late May, while Canaccord Genuity initiated at Buy with a $104 target in early June. The mean price target across the analyst group is $105, implying roughly 27% upside from the current $82.45. Raymond James is the outlier — it downgraded to Market Perform in May without attaching a new price target, a signal of valuation discomfort rather than fundamental concern. Forward EPS growth ranks in the 95th percentile of the universe, and the company has beaten estimates at a high rate — 84th percentile on EPS surprise. That growth story is the bull case anchor. The bear case centres on the standard biotech risks: trial failures, regulatory delays, and the reality that the company is still loss-making, with a negative PE and negative book value.
Institutional ownership adds meaningful context. Farallon Capital nearly doubled its stake in Q1, adding almost 5.9 million shares to hold 5.2% of the company. BlackRock added 936,000 shares through June 30, bringing its position to 7.2%. Viking Global, however, trimmed by 2 million shares through early July, cutting its stake to just under 5%. Insider activity leans negative at the margin: director Jennifer Cook sold over $16 million worth of stock in a series of transactions between mid-June and July 9, with prices ranging from $67 to $90. The 90-day net insider figure is technically positive — driven by earlier activity — but the recent directional flow is clearly selling into strength.
The July 31 print is the immediate focal point. Historical earnings reactions have been muted on day one — the prior two prints produced a 3.6% gain and a 1% loss on the next day — but both extended to gains of 8.7% and 2.3% over the following five days. With options now pricing in far more risk than has been typical, how BridgeBio frames the acoramidis commercial trajectory and pipeline progression will determine whether the PCR spike looks prescient or opportunistic.
See the live data behind this article on ORTEX.
Open BBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
